Physician profile
Udaya Kumar
NPI 1841207370
$12,262.45
in general payments reported to CMS, 2019-2025
34 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,617 · 2020: $3,548 · 2021: $3,483 · 2022: $490 · 2023: $396 · 2024: $335 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.93 |
| Education | $164.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laser Specialty Medical, LLC | $9,500.00 | 2019-2021 | |
| Astellas Pharma US INC | $589.52 | 2019-2024 | |
| Boston Scientific Corporation | $226.70 | 2023-2025 | Spaceoar Vue System - 10ml, Lithovue, Ams 700 |
| Pfizer INC. | $199.57 | 2019-2022 | |
| Teleflex LLC | $152.54 | 2021 | |
| Axonics, INC. | $140.38 | 2021-2024 | Axonics, Bulkamid |
| Medtronic USA, INC. | $129.11 | 2019 | |
| Endo Pharmaceuticals INC. | $116.18 | 2020-2023 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $104.75 | 2021-2024 | Prolaris |
| Urogen Pharma, INC. | $103.99 | 2021-2024 | |
| Myovant Sciences INC. | $99.11 | 2021-2022 | |
| Procept Biorobotics Corporation | $92.78 | 2022 | |
| Seagen INC. | $84.99 | 2025 | |
| Abbvie INC. | $84.47 | 2022-2025 | |
| Coloplast Corp | $78.54 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $69.36 | 2024-2025 | Xiaflex |
| Dendreon Pharmaceuticals LLC | $68.53 | 2021-2022 | |
| Rochester Medical Corporation | $46.73 | 2022 | |
| Sumitomo Pharma America, INC. | $45.32 | 2023-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $42.62 | 2023-2024 | Keytruda, Lynparza |
| Medtronic, INC. | $41.87 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $35.92 | 2023 | Bard Urinary Drainage Bag |
| Bayer Healthcare Pharmaceuticals INC. | $26.46 | 2023 | |
| Tolmar, INC. | $24.49 | 2023 | |
| Conmed Corporation | $24.38 | 2024 | Airseal |
| Neotract INC. | $23.99 | 2019 | |
| Blue Earth Diagnostics | $23.38 | 2024 | |
| Ferring Pharmaceuticals INC. | $21.69 | 2019 | |
| Laborie Medical Technologies Corp. | $21.66 | 2023 | |
| Gilead Sciences, INC. | $21.06 | 2023 | Veklury |
| Bioprotect Medical, INC. | $17.87 | 2024 | Bioprotect Balloon Implant System |
| Ambu INC. | $4.49 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$136,647.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udaya Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.